US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.80

+0.25001.02%

Volume:11.68K

Turnover:287.33K

Market Cap:55.68M

PE:- -

High:25.15

Open:25.09

Low:24.35

Close:24.55

52wk High:27.02

52wk Low:15.63

Shares:2.24M

Float Shares:2.24M

Volume Ratio:0.28

T/O Rate:0.52%

Dividend:1.70

Dividend Rate:6.87%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

RBC Capital Remains a Buy on GH Research (GHRS)

Analysts’ Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)

AbCellera to Report Phase 2 Menopause Therapy Data

Israel's Entera Bio Q2 Net Loss Widens

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review

Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval

NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review

THOMSON REUTERS

NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval

THOMSON REUTERS

NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting

THOMSON REUTERS

FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

THOMSON REUTERS

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Wingara Ag sets AGM to approve capital raising tools and board re-elections

Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PSIL/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.8,"timestamp":1788377215667,"preClose":24.55,"halted":0,"volume":11676,"delay":0,"changeRate":0.010183299389002037,"floatShares":2244976,"shares":2244976,"eps":0,"marketStatus":"Trading","change":0.25,"latestTime":"09-02 15:29:39 EDT","open":25.09,"high":25.145,"low":24.3501,"amount":287334.85914,"amplitude":0.032379,"askPrice":25.11,"askSize":100,"bidPrice":24.57,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":24.55,"sharesOutstanding":1184976,"nav":24.77,"aum":55609064.46,"dividendRate":0.068694,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":24.8,"preClose":24.55,"latestTime":"08:30 EDT","volume":22,"amount":539.989956,"timestamp":1788352229605,"change":0.25,"changeRate":0.010183,"amplitude":0.013035},"postHourTrading":{"tag":"盘后","latestPrice":24.55,"preClose":24.55,"latestTime":"19:56 EDT","volume":21,"amount":516.69,"timestamp":1788306978775,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.277763,"impliedVol":0.4485,"impliedVolPercentile":0.8214},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2244976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.277763,"shares":2244976,"dividePrice":1.7036,"high":25.145,"amplitude":0.032379,"preClose":24.55,"low":24.3501,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.8,"committee":0.818182,"eps":0,"divideRate":0.068694,"volume":11676,"delay":0,"ttmEps":0,"open":25.09,"prevYearClose":17.17,"prevWeekClose":25.2464,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":26.33,"twentyDayClose":24.66,"sixtyDayClose":19.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4196","BK4007","LU0029864427.USD","PTH","GHRS","GNOM","GH","BK4585","LU1267930573.SGD","BK4551","EKG","GNMX","LFSC","FFOX","LU0320765992.SGD","BK4588","PSIL","LU0708994859.HKD","BK4207","BK4535","LU0310800379.SGD","LU0889565916.HKD","GDOC","GSIB","LU0128525929.USD","HELX","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657219266","title":"Analysts’ Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657219266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657219266?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:10","pubTimestamp":1786140605,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS) and Trulieve Cannabis (TRLV)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-compass-pathways-cmps-trulieve-cannabis-trlv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-compass-pathways-cmps-trulieve-cannabis-trlv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNBS","BK4137","LU0029874061.USD","LABU","CMPS","BK4588","MSOS","BK4585","LU0128526141.USD","HCSG","TOKE","XLV","TRLV","YOLO","BK4007","BK4581","WEED","MSOX","MJ","BK4139","XBI","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657292236","title":"AbCellera to Report Phase 2 Menopause Therapy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2657292236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657292236?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:19","pubTimestamp":1786137583,"startTime":"0","endTime":"0","summary":"AbCellera Biologics ( ($ABCL) ) has provided an update. On August 7, 2026, AbCellera announced it will release top-line data from its Phase 2 trial...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-to-report-phase-2-menopause-therapy-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-to-report-phase-2-menopause-therapy-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657488626","title":"Israel's Entera Bio Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657488626","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657488626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:31","pubTimestamp":1786134710,"startTime":"0","endTime":"0","summary":"CORRECTED-Israel's Entera Bio Q2 net loss widensCorrects period in Key Details to Q2, from H1OverviewIsrael oral peptide developer reported no revenue for Q2 2026Company's net loss widened due to high","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","BK4539","PSIL","ENTX","BK4139","DTIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","XLV","BK4551","LU0029874061.USD","BK4585","HCSG","LU0889565916.HKD","SRRK","BK4007","HELX","EKG","GNOM","PSIL","INMD","LU0109394709.USD","GDOC","BK4139","GNMX","BK4082","GHRS","LABU","BK4535","BK4539","LU0128526141.USD","FFOX","BK4588","THNR","BK4581","BK4196","LU0320765992.SGD","PTH","GH","LFSC","XBI","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626537","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626537","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626537?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":"Conference Call 8:30 a.m. ET, Monday, August 10, 2026MIAMI, Aug.  07, 2026  (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341373/0/en/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQY","QDTE","FTEC","QQQM","JEPQ","TQQQ","QQQA","QLD","QQQY","QYLG","MNQmain","LABU","BK4007","NVIW.SI","BK4181","NQmain","BK4585","SQQQ","PSIL","BK4588","QQQJ","NRXP","GPIQ","TECS","QQQ","BK4218","IYW","HST","PSQ","QQQE","NDX",".IXIC","ONEQ","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640437","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657640437?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:30","pubTimestamp":1786120219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["THNR","LU0289739699.SGD","LU0868494617.USD","LU0058720904.USD","IE000M9KFDE8.USD","LU0321505868.SGD","LU1894683348.USD","LU0154236417.USD","IE00BLSP4452.SGD","BK4588","LU0225771236.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","BK4007","LU0306807586.USD","LU1057294990.SGD","PPH","OZEM","LU1894683264.USD","BK4568","LU1066051498.USD","NVOH","SG9999002224.SGD","LU0122379950.USD","IE00B19Z3581.USD","LU0306806265.USD","SG9999003800.SGD","BK4550","IE00BBT3K403.USD","LU0321505439.SGD","LU0225284248.USD","LU1093756168.USD","LU1093756325.SGD","NVO","BK4534","PSIL","BK4599","SG9999013999.USD","LU0170899867.USD","PFE","SG9999001176.USD","SG9999002232.USD","NRXP","SGXZ57979304.SGD","LU1023059063.AUD","BK4581","LU0234572021.USD","IE00B3T34201.USD","BK4592","NVOX","LU1066053197.SGD","IE00BKVL7J92.USD","SG9999011175.SGD","IE0002270589.USD","IE00BZ1G4Q59.USD","BK4585","LU0456855351.SGD","IE00BLSP4239.USD","LU2596442595.SGD","BK4533","BK4532","LU1883839398.USD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657980640","title":"NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657980640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657980640?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:24","pubTimestamp":1786119840,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals shares rose after the Food and Drug Administration completed its abbreviated new drug application review of the company's ketamine product.The stock climbed 21% to $3.73 on Friday. Shares are up 42% this year.The first-cycle review evaluated NRx's preservative-free ketamine and found no major deficiencies related to the product, ingredients or labeling, the drug company said Friday.The FDA did flag a remaining question related to the container closure of the medication vial. The issue is packaging-related and doesn't relate to the ketamine drug product itself, NRx said.The company is providing an attestation to the FDA related to the packaging issue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4585","PSIL","NRXP","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657664119","title":"Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657664119","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657664119?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:00","pubTimestamp":1786111242,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Relmada Therapeutics (RLMD), Delcath Systems (DCTH) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-relmada-therapeutics-rlmd-delcath-systems-dcth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-relmada-therapeutics-rlmd-delcath-systems-dcth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4007","DCTH","RLMD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610077","title":"FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610077","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610077?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:21","pubTimestamp":1786101688,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP) announced that the FDA has completed first-cycle review of the company’s ANDA for its preservative-free ketamine, with n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-completes-review-of-nrx-pharmaceuticals-preservative-free-ketamine-anda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-completes-review-of-nrx-pharmaceuticals-preservative-free-ketamine-anda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PSIL","NRXP","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061084","title":"FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061084","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657061084?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:01","pubTimestamp":1786100507,"startTime":"0","endTime":"0","summary":"FDA flags packaging certification as sole major deficiency for NRx preservative-free ketamine ANDA approvalFDA completed first-cycle review of NRX Pharmaceuticals’ preservative-free ketamine ANDA with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL6YBV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815337495.USD","LU0728928796.USD","FAN.UK","SG9999014039.USD","LU0282719219.EUR","PSIL","SG9999014005.SGD","LU2210150020.SGD","SG9999014021.USD","NRXP","LU1815337578.USD","LU0314104364.USD","LU2095319765.USD","LU0757432629.USD","SG9999014013.SGD","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","BK4588","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4007","IE00BGHQF748.EUR","BK5026","IE00BN0W2V16.EUR","BK4112","LU2210149790.SGD","LU0757432546.USD","LU0640478920.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617099","title":"NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617099?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617087","title":"NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617087?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657170556","title":"NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2657170556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657170556?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161707","title":"FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657161707?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699541","title":"These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699541?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:15","pubTimestamp":1786079700,"startTime":"0","endTime":"0","summary":"Biotech stocks have recaptured investors' attention this year amid a wave of drug innovation, which is spurring merger-and-acquisition activity in the biopharma industry and a fresh round of initial p","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001440.SGD","FTXH","LU0320765489.SGD","LU0122379950.USD","PSIL","GDOC","XLV","IE000M9KFDE8.USD","JDOC","FHLC","LU0965508806.USD","IXJ","IE00B1BXHZ80.USD","LU1934455194.USD","LU1430594728.SGD","HRTS","LU2125154778.USD","XBI","IHE","LU1261432733.SGD","LU2491050154.USD","BBC","LU1941712348.USD","RXL","LU0061475181.USD","LU0456855351.SGD","LU1974910355.USD","PAWZ","MEDX","IYH","BMED","LU1037948541.HKD","LU2461242641.AUD","BK4578","LU1023059063.AUD","NVS","TRUH","PPH","VHT","MRK","LU1929549753.HKD","LU1061106388.HKD","LU2596442595.SGD","BMY","SG9999014575.USD","NVIB","LU0980610538.SGD","IE00BJJMRZ35.SGD","PBLS","LU0306807586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657529664","title":"Wingara Ag sets AGM to approve capital raising tools and board re-elections","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657529664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:29","pubTimestamp":1786058949,"startTime":"0","endTime":"0","summary":"Wingara Ag Ltd. ( ($AU:WNR) ) has issued an update. Wingara Ag Ltd has called its Annual General Meeting for 7 September 2026 in Melbourne, where s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","AGM","BK4229","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666177","title":"Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666177","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666177?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:49","pubTimestamp":1786052975,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryRelmada Therapeutics IncRLMD.OQreported a quarterly adjusted loss of 11 cents per share for the quarter ended J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657931666","title":"Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657931666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657931666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:41","pubTimestamp":1786052519,"startTime":"0","endTime":"0","summary":"Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancerRelmada outlined NDV-01 as its lead program, a sustained-release intravesical gemcitabine/doce","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1WTVbn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00B4R5TH58.HKD","LU0109394709.USD","BK4539","IBRN","NBIX","BK4563","LU0823416689.USD","BK4007","LU2324357040.USD","LU0154245673.USD","SBIO","BK4139","GHRS","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IMRX","LU2065171402.SGD","PSIL","IE00BFTCPJ56.SGD","LU2065170008.USD","LU0154245756.USD","IE0002141913.USD","PRAX","LU0320765992.SGD","LU2065171311.SGD","LU2065169927.USD","XENE","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}